Proxima

Join us for an evening social at ICLR, hosted by Proxima and NVIDIA Healthcare Rooftop bar, bites, and a curated room of researchers, founders, and engineers at the intersection of AI x Bio. Spots are limited. RSVP here: https://luma.com/AIxBio

Drug discovery has a scale problem. The complexes that govern signaling, regulation, and disease aren't single proteins, or even tidy pairs. They're sprawling assemblies of 10, 20, even 50+ subunits. The field is forced to sidestep that level of complexity, not for lack of interest, but for lack of tools. And yet, simulating cellular biology requires modeling the complexes and interactions these proteins form, not just individual proteins. NeoLink, Proxima's proteomics platform, has experimentally mapped millions of protein-protein interactions across these higher-order complexes. Predicting their structures at this scale demanded something new. We built it with NVIDIA Healthcare. By integrating NVIDIA's Fold-CP into our pipeline, we distribute computation for long biological sequences across multiple GPUs, removing the memory bottleneck that kept these complexes out of reach. New preprint out now with the NVIDIA BioNeMo team: https://bit.ly/4rDQnXA

We are adding world-class expertise to our Scientific Advisory Board at Proxima: Dr. Ray Deshaies, Ph.D.: co-inventor of PROTACs, National Academy of Sciences member, fmr SVP Global Research at Amgen Dr. Lyn Jones: molecular glue leader, fmr Head of Chemical Biology at Pfizer, PI at Dana-Farber Dr. Juri Rappsilber: pioneer of cross-linking mass spectrometry, Chair of Bioanalytics at TU Berlin We're excited to tap their deep expertise in target biology, medicinal chemistry, and structural proteomics as we build the platform for rational design of proximity-based medicines. Press release: https://bit.ly/4d4dYwV

Thrilled to have DCVC and NVIDIA alongside us as we build the platform for proximity-based medicines. We're just getting started: multiple exciting announcements coming soon. If you want to work on frontier ML models and an unprecedented biological data generation engine, we'd love to hear from you: recruiting@proximabio.com

Excited to announce that our team at Proxima (formerly VantAI) has raised $80M led by DCVC with participation from NVIDIA, Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Real Estate Equities, Inc., Modi Ventures, and others. This funding accelerates our mission to build the platform for proximity-based medicines - molecular glues, PROTACs, and the next generation of therapeutics targeting the vast majority of protein interactions that remain structurally uncharted. Links: Bloomberg Exclusive: https://bit.ly/3LaM1Iw Press Release: https://bit.ly/4jJG6qI Website: https://proximabio.com/

📢 The VantAI team is thrilled to be at NeurIPS 2025! 💥 If you’re interested in meeting with a member of our team for a coffee chat, drop your details at this link and we’ll follow up to schedule https://lnkd.in/eT7QBJmF

We're thrilled to partner with Halda Therapeutics to expand the reach of their groundbreaking RIPTAC platform. Together, we're working to identify new therapeutic target-effector combinations that will help enable this innovative proximity-based approach to unlock new treatment possibilities across cancer and immune disorders. Read more: http://bit.ly/4monuwV

Neo just got much faster! 💥 Working closely with NVIDIA Healthcare, VantAI adopted #cuEquivariance, leading to massive speedups. Today's announcement is a big advancement for the field! Read more: nvda.ws/4jHJFM6 Try now: https://lnkd.in/ddXqW9dE

🧬 Excited to announce our second expansion in three years with Blueprint Medicines. 🧪 Together, we will prioritize novel target-effector pairs for molecular glue development, aiming at previously undruggable targets, using our proximity modulator discovery platform powered by our Neo-1 foundation model and NeoLink XLMS technology. The collaboration includes up to $1.67B in potential milestone payments. See press release for more details: https://lnkd.in/eF3fB-4K